1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) is sponsored by National Institutes of Health (NIH). This NIH SBIR omnibus solicitation is for small businesses proposing projects that include a clinical trial.
Causal inference is a critical methodology in clinical trials for evaluating the effectiveness of interventions and understanding treatment effects, making it highly relevant to this funding opportunity.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-owned and -operated small businesses engaging in research and development activities with strong potential for commercialization, including those involving clinical trials. Confirm the full requirements in the official notice before applying.
The current listing shows up to $325,000 for Phase I; up to $2,000,000 for Phase II (with some waivers allowing higher amounts). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) are due September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read article